Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
With its $350M in new funding, EliseAI said it plans to build out its technology and sales force. Currently, it works with specialty provider groups to automate practice operations such as scheduling and insurance verification.
Of surveyed and interviewed U.S. physicians who showed significant six-month improvement in follow-up vs. baseline wellness checks, 47% attributed the gain to active personal changes. Not far behind were those who credited active work-related changes—40% of the field.
The new entity, Precure, will be owned by both groups. Its work in detecting early disease for timely intervention stems from a research project launched this summer. The Mayo Clinic said Precure will make the results of that initiative actionable.
A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.
A global tech and pharma vendor is set to inject U.S. healthcare with a set of generic contrast agents, the first of which will be an FDA-approved substitute for GE Healthcare’s Visipaque.
A healthcare AI startup in Silicon Valley is partnering with a top-tier medical school—and hopefully a few good radiologists—to test a hypothesis that’s increasingly crucial to radiology.
GE HealthCare will be the name of the company’s healthcare business, while its energy portfolio will go under the moniker GE Vernova, and its aviation business will be dubbed GE Aerospace.
Portable MRI maker Hyperfine is touting a new capability in its Swoop scanner that may appeal to pediatric neurologists and neurosurgeons as well as neuroradiologists.
A machine learning system for planning spine surgery that also predicts post-op spinal alignment six months out has cleared the FDA’s 510(k) review process.